Zdrowie i gospodarka · 14/02/2012

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee to Review Amendment of Notice Regarding New Drug Applications

The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will review an amendment to a notice regarding new drug applications, a process aimed at ensuring the safety and efficacy of new treatments for skin and eye conditions